ALL-090 Highly Effective Combination of FLT3 and BCL2 Inhibitors in a Preclinical Model of Lineage Ambiguous Leukemia

Context: Lineage ambiguous leukemias are rare leukemia subtypes with diagnostic and treatment challenges and poor outcomes. We recently described a new subtype of lineage ambiguous leukemia defined by aberrant BCL11B activation (“BCL11B-a”) which included 30%–40% of T/myeloid mixed-phenotype acute l...

Celý popis

Podrobná bibliografie

Vydáno v:	Clinical lymphoma, myeloma and leukemia Ročník 22; s. S193 - S194
Hlavní autoři:	Montefiori, Lindsey, lacobucci, Ilaria, Budhraja, Amit, Moore, Jamila, Baskin, Rebekah, DeVries, Rebekah, Backhaus, Emily, Johnson, Melissa, Akers, Walter, Chepyala, Divyabharathi, Mehr, Cyrus, Seth, Aman, Mead, Paul, Opferman, Joseph, Mullighan, Charles
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Elsevier Inc 01.10.2022
Témata:	ALL BCL11B gilteritinib lineage-ambiguous MPAL venetoclax ALL lineage-ambiguous gilteritinib MPAL BCL11B venetoclax
ISSN:	2152-2650
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!